While rebates may still be unavailable in 2027 for employers that cover GLP-1s only for obesity-related conditions but not for the broader weight loss indication, the potential impact may be smaller with a lower list price
Research shows BPC-157 has systemic effects regardless of injection location due to its stability and distribution throughout the body
HSA and FSA accounts cover PlexusDx medications, offering tax-advantaged payment options for self-directed health spending
Monteiro P, Duarte AI, Goncalves LM, Moreno A, Providencia LA
This difference matters even more when absorption is compromised, as it is with GLP-1 medications
Clinical studies have shown that individuals using Tirzepatide alongside a healthy diet and exercise can lose an average of 20% of their body weight , making it one of the most effective non-surgical options available today